CompoAtlas

康優特第二代軟膠囊 (食品)

康優特第二代軟膠囊 (食品) : Product registered in Taiwan. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

TFDA, Taiwan tablets, capsules and medical nutrition registers, retrieved 27 October 2026.

Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0

Open Government Data License, version 1.0

The foreign register category does not determine the regulatory category of the product in France.

French and European references for recognised ingredients

Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.

Published composition

Published ingredientPublished text and quantityIdentified nutrient or substance
FLAX SEED OILFLAX SEED OILNot identified
NOTOGINSENG EXTRACTNOTOGINSENG EXTRACTNot identified
GINSENG RADIX EXTRACTGINSENG RADIX EXTRACTNot identified
SALVIA ROOT EXTRACTSALVIA ROOT EXTRACTNot identified
HAWTHORN EXTRACTHAWTHORN EXTRACTNot identified
MAGNESIUM HVP CHELATEMAGNESIUM HVP CHELATEMagnésium
COENZYME Q10COENZYME Q10Ubiquinone
OPHIOPOGONIS RADIX EXTRACTOPHIOPOGONIS RADIX EXTRACTNot identified
SCHISANDRA EXTRACTSCHISANDRA EXTRACTNot identified
LECITHINLECITHINNot identified
YELLOW BEESWAXYELLOW BEESWAXNot identified
PIG SKIN GELATINPIG SKIN GELATINNot identified
GLYCEROLGLYCEROLGlycérol
PURIFIED WATERPURIFIED WATERNot identified
TITANIUM DIOXIDETITANIUM DIOXIDENot identified
ALLURA RED ACALLURA RED ACNot identified
SUNSET YELLOW FCFSUNSET YELLOW FCFNot identified
BRILLIANT BLUE FCFBRILLIANT BLUE FCFNot identified

The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.

Product record

Registration number
1110600358
Chinese name
康優特第二代軟膠囊 (食品)
English name
CAN YOUNG NO.2 SOFTGELS
Type
Imported tablets and capsules
Published status
Status not provided in this export; the validity date is shown separately
Licence holder
九泰生醫有限公司
Registration date
2022-01-28
Published validity end
2027-01-28

Original register data

View published fields and their variants
Product name
康優特第二代軟膠囊 (食品)
Active ingredients
FLAX SEED OIL;;NOTOGINSENG EXTRACT;;GINSENG RADIX EXTRACT;;SALVIA ROOT EXTRACT;;HAWTHORN EXTRACT;;MAGNESIUM HVP CHELATE;;COENZYME Q10;;OPHIOPOGONIS RADIX EXTRACT;;SCHISANDRA EXTRACT;;LECITHIN;;YELLOW BEESWAX;;PIG SKIN GELATIN;;GLYCEROL;;PURIFIED WATER;;TITANIUM DIOXIDE;;ALLURA RED AC;;SUNSET YELLOW FCF;;BRILLIANT BLUE FCF;;
Valid until
1160128
Registration number
1110600358
Licence holder
九泰生醫有限公司
Registration date
1110128
Published reference
DHC0B106003580
Published English name
CAN YOUNG NO.2 SOFTGELS

Official source

View the official register, number 1110600358

Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0

Open Government Data License, version 1.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • COENZYME Q10
    Read the warning, when it applies and the studies cited

    Coenzyme Q10 (UBIQUINONE-10)

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).

    Sources cited by Health Canada (2)
    • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
    • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial

    Applies to products providing more than 100 mg of Coenzyme Q10 per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (3)
    • Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Condition of application: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Health Canada monograph dated 31 January 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line